Antonio Kösters

Antonio Kösters

Auto-generated profile, based on publicly available information

Antonio Kösters

Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna , Spitalgasse 23, Vienna 1090

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2026 in European Heart Journal Open
Verified
Journal Article
Open access
AKAntonio Kösters
Antonio Kösters
MEMahshid Eslami
Mahshid Eslami
ESElisabetta Salvioni
Elisabetta Salvioni
NENikita Ermolaev
Nikita Ermolaev
LSLisa Seilinger
Lisa Seilinger
RERoza Badr Eslam
Roza Badr Eslam
Aims: Oxygen uptake at the first ventilatory threshold (VT1) can be expressed as an absolute value (VO2VT1-abs), as a percentage of predicted peak VO2 (VO2VT1-%pred), or as a percentage of observed peak VO2 (VO2VT1-%obs). We compared their prognostic performance in transthyretin cardiac amyloidosis (ATTR-CM). Methods and Results: Adults with ATTR-CM undergoing baseline cardiopulmonary exercise testing at two centres were studied. Endpoints were all-cause mortality and death or heart failure (HF) hospitalisation. Censoring-aware 2-year discrimination and age- and sex-adjusted Cox associations were assessed. Incremental model fit and discrimination beyond age, sex, peak VO2, and VE/VCO2 slope were evaluated, with bootstrap internal validation. Among 182 patients, VT1 was identifiable in 173 (95.1%). Mortality follow-up was available in 162 patients (44 deaths), and composite follow-up in 157 (66 events). Per 1-standard-deviation decrease, VO2VT1-abs and VO2VT1-%pred were associated with mortality (hazard ratio [HR] 2.86, 95% confidence interval [CI] 1.77–4.63; and HR 2.50, 95% CI 1.61–3.87; both P<0.001) and the composite endpoint (HR 2.25, 95% CI 1.53–3.31; and HR 2.38, 95% CI 1.65–3.43; both P<0.001). VO2VT1-%obs was not associated with either endpoint. Adding VO2VT1-abs or VO2VT1-%pred improved mortality model fit (likelihood-ratio P=0.019 and P=0.034), but bootstrap 95% CIs for both gains in C-index included zero. Severe-limitation analyses were exploratory, without significant interactions. Conclusion: Absolute and predicted-normalised VT1 were associated with outcomes; non-proportional hazards warrant caution for absolute-VT1 mortality. Improved model fit does not establish improved predictive discrimination, clinical utility, or added value beyond comprehensive ATTR-CM risk stratification. External validation is required.

Verified
Journal Article
Open access
PDF file
MEMahshid Eslami
Mahshid Eslami
AKAntonio Kösters
Antonio Kösters
NENikita Ermolaev
Nikita Ermolaev
BGBernhard Gregshammer
Bernhard Gregshammer
CKChristina Kronberger
Christina Kronberger
RERoza Badr Eslam
Roza Badr Eslam
Background: Hereditary transthyretin amyloidosis (ATTRv) is a progressive multisystem disease, and some patients continue to deteriorate despite disease-modifying therapy. Real-world data on sequential treatment and on eplontersen after prior gene-silencing therapy are scarce. Case Presentation: A 60-year-old man with a family history suggestive of amyloidosis presented in early 2017 with heart failure (NYHA class II–III), chronic diarrhoea and carpal tunnel syndrome. Multimodality imaging, grade 3 bone scintigraphy, exclusion of a monoclonal protein (negative immunofixation and a normal serum free light chain ratio) and genetic testing established ATTRv amyloidosis due to the p.Thr80Ala variant, and colonic and duodenal biopsies showed gastrointestinal amyloid deposits. Between 2017 and 2025 he was treated sequentially with tafamidis, patisiran and vutrisiran. Over this period the disease progressed clinically, with weight loss, worsening axonal polyneuropathy on nerve conduction studies, rising NT-proBNP (up to 3808 pg/mL) and a decline in six-minute walk distance. In July 2025, vutrisiran was replaced by eplontersen. During 15 months of follow-up, eplontersen was well tolerated and body weight increased from 54 to 57 kg. NT-proBNP fluctuated without a sustained further rise (3093 pg/mL at the switch and 3141 pg/mL at 15 months), and troponin T and renal function were unchanged, whereas diarrhoea persisted and the six-minute walk distance was 360 m. Conclusions: This case shows clinical progression of p.Thr80Ala ATTRv amyloidosis despite sequential stabiliser and small interfering RNA therapy, followed by clinical stabilisation after a switch to eplontersen. Without serum TTR measurements and in a single patient, these observations do not allow conclusions about treatment efficacy.

23 July 2026 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
AKAntonio Kösters
Antonio Kösters
NENikita Ermolaev
Nikita Ermolaev
ESElisabetta Salvioni
Elisabetta Salvioni
MEMahshid Eslami
Mahshid Eslami
LSLisa Seilinger
Lisa Seilinger
MMMassimo Mapelli
Massimo Mapelli
Aims: To evaluate the applicability of the RoMa classification in patients with transthyretin cardiac amyloidosis (ATTR-CM) and to assess its association with functional capacity and key cardiopulmonary exercise testing (CPET) parameters. Methods and results: Consecutive adults (≥18 years) with confirmed ATTR-CM from two tertiary centres who completed symptom-limited maximal CPET were included. RoMa classes were defined using predefined cut-offs for per cent-predicted peak heart rate (HRpp ≥80%) and per cent-predicted peak O2-pulse (O2pp ≥100%): RoMa I (high HRpp/high O2pp), RoMa II (high HRpp/low O2pp), RoMa III (low HRpp/high O2pp), and RoMa IV (low HRpp/low O2pp). We evaluated 165 patients (90% male; 77% wild-type ATTR, 20% variant ATTR). RoMa distribution was as follows: RoMa I, n = 33; RoMa II, n = 73; RoMa III, n = 30; and RoMa IV, n = 29. Age did not differ across classes (P = 0.36). Functional capacity declined across the RoMa strata: median 6-min walk distance (6MWD) decreased from 420 (RoMa I) to 313 m (RoMa IV) (overall P = 0.009; P-trend = 0.005), and NYHA class worsened (overall P = 0.003; P-trend = 0.005). Peak VO2 (% predicted) differed between groups (RoMa I: 93.0; II: 70.8; III: 75.2; IV: 51.9; overall P < 0.001; P-trend < 0.001), and ventilatory inefficiency increased (VE/VCO2 slope: 34; 39; 37; 47, respectively; overall P < 0.001; P-trend < 0.001; peak PetCO2: 30; 27; 29; 25, respectively; overall P < 0.001; P-trend = 0.003). 6MWD correlated with peak VO2 (r = 0.626; P < 0.001; n = 131) and inversely with VE/VCO2 slope (ρ = −0.484; P < 0.001; n = 130). Conclusion: In ATTR-CM, application of the RoMa classification was feasible and identified distinct CPET-derived exercise-response profiles associated with functional impairment. These findings support RoMa as a promising exploratory framework for functional phenotyping in ATTR-CM.

22 October 2026 in European Heart Journal Open
Verified
Journal Article
Open access
AKAntonio Kösters
Antonio Kösters
NENikita Ermolaev
Nikita Ermolaev
MEMahshid Eslami
Mahshid Eslami
LLLeonhard Lichtblau
Leonhard Lichtblau
LSLisa Seilinger
Lisa Seilinger
RERoza Badr Eslam
Roza Badr Eslam
Aims: To assess the association of 1-min heart rate recovery (HRR1) with clinical outcomes and its incremental contribution to model fit beyond peak VO2 and ventilatory efficiency (VE/VCO2 slope) in transthyretin cardiac amyloidosis (ATTR-CM). Methods and results: Consecutive adults with confirmed ATTR-CM undergoing symptom-limited cardiopulmonary exercise testing (CPET) were included in this single-centre observational study. During standardized active recovery at 24 W, HRR1 was defined as peak heart rate minus heart rate exactly 60 s after exercise. Cox proportional-hazards models evaluated all-cause mortality and the composite of mortality or first heart-failure hospitalization. Principal models adjusted for age, sex, peak VO2 and VE/VCO2 slope; NT-proBNP and National Amyloidosis Centre (NAC) stage were examined separately. Of 161 baseline patients, 11 with unverifiable heart-rate measurements were excluded, and exact HRR1 was available in 110. Mortality analysis included 105 patients with 33 deaths; composite-outcome analysis included 107 patients with 51 events. Median HRR1 was 15.5 bpm. In conventional CPET-adjusted models, each 10-bpm greater HRR1 was associated with lower hazards of mortality [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.44–0.95; P = 0.028] and the composite outcome (HR 0.74, 95% CI 0.57–0.97; P = 0.029). Adding HRR1 improved model fit (likelihood-ratio P = 0.017 and P = 0.021, respectively); apparent C-indices increased from 0.770 to 0.795 for mortality and from 0.695 to 0.699 for the composite outcome. Associations were non-significant after separate adjustment for NT-proBNP or NAC stage. Conclusion: HRR1 remained associated with outcomes after CPET adjustment and improved model fit. Discrimination gains were modest; value beyond biomarker staging was unproven.